FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington,	D.C.	20549	

STATEMENT	OF CHANGES IN	I BENEFICIAL	<b>OWNERSHIP</b>
O 17 (1 E IVI E I V I	0. 0.0.0.000	. DE: 10:/ 10	O 1111E1 (O1111

	OMB APP	ROVAL
	OMB Number:	3235-0287
	Estimated average b	ourden
- 1	hours nor recogness:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  HANISH ARNOLD C					2. Issuer Name <b>and</b> Ticker or Trading Symbol Salarius Pharmaceuticals, Inc. [ SLRX ]								c all appli Directo	cable) or	g Per	son(s) to Iss	vner	
(Last)	•	rst) (	Middle)		3. Date of Earliest Transaction (Month/Day/Year) 03/23/2020								Officer below)	(give title		Other (s below)	specify	
2450 HOLCOMBE BLVD., SUITE J - 608				4. I	If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable						
(Street)	ON T	K :	77021								ine) X	•						
(City)	(Si	ate) (	(Zip)															
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)				Execution Date,		Code (Instr. 5)			4 and Securitie Beneficia		es Forn ially (D) o Following (I) (Ir		n: Direct r Indirect istr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
						Code	,	Amount	(A) or (D)		e	Transaci (Instr. 3	ction(s)					
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	Derivative Conversion Date Execution Date, To Conversion Or Exercise (Month/Day/Year) if any			ansaction of I ode (Instr. Derivative (		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Securit (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
				Code			Date Exercisable	Exp Dat	piration te	Title	Amour or Number of Shares	nber						
Stock Option (right to buy)	\$0.61	03/23/2020		A		6,000		(1)	03/2	/22/2030	Common Stock	6,00	0	\$0	6,000		D	

## **Explanation of Responses:**

1. Options granted are fully vested on March 23, 2021.

## Remarks:

s/ Arnold C. Hanish

03/25/2020

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

 $<sup>^{\</sup>star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

<sup>\*\*</sup> Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).